Lexicon Pharmaceuticals Reports Significant Revenue Decline and Increased Net Loss in Q2 2026

Lexicon Pharmaceuticals, Inc. reported a significant decline in financial performance for the second quarter of 2026, with total revenues of $0.7 million compared to $28.9 million in the same period of 2025. The decrease was primarily attributed to a lack of licensing and milestone revenue, which had contributed $27.5 million in the previous year. For the first half of 2026, revenues totaled $21.8 million, down from $30.1 million in the first half of 2025. The company’s net loss for the quarter was $31.8 million, or $0.07 per share, contrasting sharply with a net income of $3.3 million, or $0.01 per share, in the prior year.

In terms of operational changes, Lexicon's research and development expenses increased by 11% to $17.4 million for the second quarter, driven by higher costs associated with clinical trials for its drug candidates. However, selling, general, and administrative expenses saw a slight increase of 4% to $9.8 million, reflecting ongoing efforts to support the commercialization of its approved drug, INPEFA® (sotagliflozin). The company’s accumulated deficit rose to approximately $2.1 billion as of June 30, 2026, indicating ongoing challenges in achieving profitability.

Strategically, Lexicon has made notable advancements, including the completion of patient enrollment in its pivotal Phase 3 clinical trial for sotagliflozin in hypertrophic cardiomyopathy. The company also entered into a significant licensing agreement with Novo Nordisk for its preclinical drug candidate LX9851, which has the potential to generate substantial milestone payments and royalties. Additionally, Lexicon secured a $100 million loan agreement with Hercules Capital, which provides financial flexibility for ongoing research and development activities.

As of June 30, 2026, Lexicon's total assets increased to $250.1 million, up from $185.0 million at the end of 2025, largely due to cash inflows from stock issuances. The company reported cash and cash equivalents of $40.9 million, alongside short-term investments of $149.7 million. Looking ahead, Lexicon anticipates continued investment in its drug development pipeline and expects to rely on strategic collaborations and potential equity financing to support its operations. The company believes its current cash reserves will be sufficient to fund operations for at least the next 12 months, although it acknowledges the need for additional financing in the future to sustain its growth and development initiatives.